Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites - PubMed (original) (raw)
- PMID: 4027393
- DOI: 10.1007/BF01806018
Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites
B S Katzenellenbogen et al. Breast Cancer Res Treat. 1985.
Abstract
Antiestrogens have proven to be effective in controlling the growth of hormone-responsive breast cancers. At the concentrations of antiestrogens achieved in the blood of breast cancer patients taking antiestrogens (up to 2 X 10(-6) M), antiestrogens selectively inhibit the proliferation of estrogen receptor-containing breast cancer cells, and this inhibition is reversible by estradiol. Antiestrogens also inhibit estrogen-stimulation of several specific protein synthetic activities in breast cancer cells, including increases in plasminogen activator activity, progesterone receptor levels and production of several secreted glycoproteins and intracellular proteins. Antiestrogens bind with high affinity to the estrogen receptor and to additional microsomal binding sites to which estrogens do not bind. These latter sites, called antiestrogen binding sites (AEBS), are present in equal concentrations in estrogen receptor-positive and -negative breast cancer cells and are present in a wide variety of tissues, with highest concentrations being found in the liver. The antiestrogenic and growth suppressive potencies of a variety of antiestrogens correlate best with their affinity for estrogen receptor and not with affinity for AEBS. Antiestrogens undergo bioactivation and metabolism in vivo and hydroxylated forms of the antiestrogen have markedly enhanced affinities for the estrogen receptor. Detailed studies with high affinity radiolabelled antiestrogens indicate that antiestrogens induce important conformational changes in receptor that are reflected in the enhanced maintenance of a 5 S form of the estrogen receptor complex; reduced interaction with DNA; and altered activation and dissociation kinetics of the antiestrogen-estrogen receptor complex. These conformational changes effected by antiestrogens likely result in different interactions with chromatin, causing altered cell proliferation and protein synthesis. Analyses of the rates of synthesis and turnover of the estrogen receptor through pulse-chase experiments utilizing the covalently attaching antiestrogen, tamoxifen aziridine, and studies employing dense amino acid labeling of estrogen receptor reveal that the antiestrogen-occupied receptor is degraded at a rate (t 1/2 = 4 h) similar to that of the control unoccupied receptor. Hence, antiestrogens do not prevent estrogen receptor synthesis and they do not either accelerate or block estrogen receptor degradation.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA, Lippman ME, Katzenellenbogen BS. Miller MA, et al. Cancer Res. 1984 Nov;44(11):5038-45. Cancer Res. 1984. PMID: 6488162 - Antiestrogen pharmacology and mechanism of action.
Katzenellenbogen BS, Miller MA, Eckert RL, Sudo K. Katzenellenbogen BS, et al. J Steroid Biochem. 1983 Jul;19(1A):59-68. J Steroid Biochem. 1983. PMID: 6887873 - William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer.
Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM. Katzenellenbogen BS, et al. Breast Cancer Res Treat. 1997 May;44(1):23-38. doi: 10.1023/a:1005835428423. Breast Cancer Res Treat. 1997. PMID: 9164675 Review. - Steroidal and nonsteroidal antiestrogens in breast cancer cells in culture.
Rochefort H, Bardon S, Chalbos D, Vignon F. Rochefort H, et al. J Steroid Biochem. 1984 Jan;20(1):105-10. doi: 10.1016/0022-4731(84)90196-1. J Steroid Biochem. 1984. PMID: 6368983 Review.
Cited by
- Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT, Venkatraman G, Liu RZ, Tang X, Mi S, Benesch MG, Mackey JR, Godbout R, Curtis JM, McMullen TP, Brindley DN. Bekele RT, et al. Sci Rep. 2016 Feb 17;6:21164. doi: 10.1038/srep21164. Sci Rep. 2016. PMID: 26883574 Free PMC article. - MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O, Wiemann S. Ward A, et al. J Pathol. 2014 Aug;233(4):368-79. doi: 10.1002/path.4363. Epub 2014 Jun 2. J Pathol. 2014. PMID: 24752803 Free PMC article. - Tamoxifen resistance in breast cancer.
Chang M. Chang M. Biomol Ther (Seoul). 2012 May;20(3):256-67. doi: 10.4062/biomolther.2012.20.3.256. Biomol Ther (Seoul). 2012. PMID: 24130921 Free PMC article. Review. - An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.
Huang L, Zhao S, Frasor JM, Dai Y. Huang L, et al. PLoS One. 2011;6(7):e22274. doi: 10.1371/journal.pone.0022274. Epub 2011 Jul 15. PLoS One. 2011. PMID: 21789246 Free PMC article. - Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
MacCallum J, Cummings J, Dixon JM, Miller WR. MacCallum J, et al. Br J Cancer. 2000 May;82(10):1629-35. doi: 10.1054/bjoc.2000.1120. Br J Cancer. 2000. PMID: 10817496 Free PMC article.
References
- Cancer Res. 1982 Jan;42(1):139-44 - PubMed
- J Biol Chem. 1981 Mar 25;256(6):2908-15 - PubMed
- Eur J Cancer Clin Oncol. 1983 May;19(5):615-21 - PubMed
- Cancer Treat Rep. 1976 Oct;60(10):1451-9 - PubMed
- Endocrinology. 1983 Feb;112(2):425-34 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials